Douglas J. Swirsky Acquires 50,000 Shares of MaxCyte, Inc. (NASDAQ:MXCT) Stock

Key Points

• Douglas J. Swirsky, CFO of MaxCyte, Inc., bought 50,000 shares at an average cost of $1.29, increasing his total holdings to 161,811 shares.
• Following a quarterly earnings report, MaxCyte missed analysts' EPS estimates and reported a negative return on equity of 22.12% with a revenue of $8.51 million.
• Institutional investors hold 68.81% of MaxCyte's stock, with several recent investments boosting their positions significantly during the 2nd quarter.

MaxCyte, Inc. (NASDAQ:MXCT - Get Free Report) CFO Douglas J. Swirsky acquired 50,000 shares of the business's stock in a transaction that occurred on Wednesday, August 13th. The stock was purchased at an average price of $1.29 per share, for a total transaction of $64,500.00. Following the acquisition, the chief financial officer directly owned 161,811 shares in the company, valued at approximately $208,736.19. This trade represents a 44.72% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

MaxCyte Price Performance

Shares of MXCT stock traded up $0.02 during trading hours on Monday, reaching $1.38. 168,880 shares of the stock were exchanged, compared to its average volume of 771,797. The business's fifty day moving average is $2.07 and its two-hundred day moving average is $2.67. The firm has a market capitalization of $146.59 million, a P/E ratio of -3.20 and a beta of 1.23. MaxCyte, Inc. has a 12-month low of $1.26 and a 12-month high of $5.20.

MaxCyte (NASDAQ:MXCT - Get Free Report) last announced its quarterly earnings data on Wednesday, August 6th. The company reported ($0.12) EPS for the quarter, missing analysts' consensus estimates of ($0.10) by ($0.02). The firm had revenue of $8.51 million during the quarter, compared to analysts' expectations of $9.57 million. MaxCyte had a negative net margin of 125.22% and a negative return on equity of 22.12%. As a group, equities research analysts predict that MaxCyte, Inc. will post -0.42 earnings per share for the current fiscal year.

Institutional Trading of MaxCyte

Institutional investors have recently bought and sold shares of the business. Lazard Asset Management LLC increased its holdings in shares of MaxCyte by 94.2% in the 2nd quarter. Lazard Asset Management LLC now owns 284,498 shares of the company's stock valued at $620,000 after acquiring an additional 137,983 shares during the last quarter. BNP Paribas Financial Markets boosted its holdings in MaxCyte by 266.6% in the second quarter. BNP Paribas Financial Markets now owns 26,008 shares of the company's stock valued at $57,000 after purchasing an additional 18,913 shares in the last quarter. Bridgeway Capital Management LLC acquired a new position in MaxCyte in the second quarter valued at approximately $272,000. Bank of America Corp DE increased its stake in MaxCyte by 54.1% in the second quarter. Bank of America Corp DE now owns 84,836 shares of the company's stock valued at $185,000 after purchasing an additional 29,771 shares during the last quarter. Finally, AXA S.A. raised its holdings in MaxCyte by 123.2% during the second quarter. AXA S.A. now owns 2,202,378 shares of the company's stock worth $4,801,000 after purchasing an additional 1,215,481 shares in the last quarter. 68.81% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on MXCT shares. William Blair cut shares of MaxCyte from an "outperform" rating to a "market perform" rating in a report on Thursday, August 7th. BTIG Research restated a "neutral" rating on shares of MaxCyte in a research note on Monday, August 11th. Wall Street Zen cut MaxCyte from a "hold" rating to a "sell" rating in a research note on Saturday, August 9th. Finally, Stephens initiated coverage on MaxCyte in a report on Tuesday, July 22nd. They issued an "overweight" rating and a $6.00 target price for the company. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have issued a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus price target of $7.00.

MaxCyte Company Profile

MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.